{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-036896","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2022-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.708947+00:00","generated_at":"2026-06-23T04:00:26.467153+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA allows Galectin Therapeutics to proceed with Phase 2 trial of belapectin + Keytruda in head and neck cancer","bullets":["FDA issued 'Study May Proceed' letter for Phase 2 trial of belapectin + pembrolizumab as first-line therapy for recurrent/metastatic PD-L1 positive head and neck squamous cell carcinoma.","This IND is the company's second; prior investigator-initiated study provided rationale for combination.","Company expects to complete enrollment in pivotal NAVIGATE trial in NASH cirrhosis around end of 2022.","Company plans to engage potential partners for oncology program; financing and trial start could occur next year."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-036896","json":"https://secwatch.observer/filing/0001140361-22-036896.json","markdown":"https://secwatch.observer/filing/0001140361-22-036896.md","text":"https://secwatch.observer/filing/0001140361-22-036896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122036896/0001140361-22-036896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122036896/ny20005256x3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:00:26.467153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}